Over the past three years, using its in-silico discovery platform for predictive drug discovery (i.e. computer models and algorithms), Compugen Ltd. (USA) (NASDAQ:CGEN) has developed a hugely compelling drug Pipeline across several clinical areas. Compugen Ltd. (USA) (NASDAQ:CGEN) stock performance was -20.14% in last session and finished the day at $11.34. Traded volume was 22,668.00 shares in the last session and the average volume of the stock remained 500,829.00 shares. The beta of the stock remained 1.77. Compugen Ltd. (USA) (NASDAQ:CGEN) insider ownership is 10.04%.

Sinovac Biotech Ltd. (NASDAQ:SVA) rallied on Thursday after the development-stage drugmaker said its Enterovirus 71 vaccine was nearly perfect protecting infants and young children from herpangina and the coxsackie virus during Phase III. Sinovac Biotech Ltd. (NASDAQ:SVA) dropped -1.94% to $6.57 yesterday on volume of 0.00 shares. The intra-day range of the stock was $6.51 – $7.10. Sinovac Biotech Ltd. (NASDAQ:SVA) has a market capitalization of 363.86 million.

Enzymotec Ltd (NASDAQ:ENZY) announced the pricing of a registered secondary public offering.
Enzymotec Ltd (NASDAQ:ENZY)’s stock on Februry 28, 2014 reported a lower of -4.62% to the closing price of $27.90. Its fifty two weeks range is $14.25 – $35.12. The total market capitalization recorded 601.33 million. The overall volume in the last trading session was 0.00 shares. In its share capital, Enzymotec Ltd (NASDAQ:ENZY) has 21.55 million outstanding shares.

Cempra Inc. (NASDAQ:CEMP) is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. On Friday, shares of Cempra Inc. (NASDAQ:CEMP) dropped -12.18% to close the day at $11.39. Company return on investment (ROI) is – and its monthly performance is recorded as -3.39%. Cempra Inc. (NASDAQ:CEMP) quarterly revenue growth is -8.00%.